SANUWAVE Health (OTCMKTS:SNWV) and SI-Bone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.
This table compares SANUWAVE Health and SI-Bone’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for SANUWAVE Health and SI-Bone, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-Bone has a consensus target price of $24.75, indicating a potential upside of 31.79%. Given SI-Bone’s higher probable upside, analysts plainly believe SI-Bone is more favorable than SANUWAVE Health.
Valuation and Earnings
This table compares SANUWAVE Health and SI-Bone’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SANUWAVE Health||$1.85 million||14.28||-$11.63 million||($0.08)||-1.75|
|SI-Bone||$55.38 million||8.33||-$17.45 million||($0.71)||-26.45|
SANUWAVE Health has higher earnings, but lower revenue than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than SANUWAVE Health, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.4% of SANUWAVE Health shares are owned by institutional investors. Comparatively, 38.9% of SI-Bone shares are owned by institutional investors. 23.4% of SANUWAVE Health shares are owned by insiders. Comparatively, 38.8% of SI-Bone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SI-Bone beats SANUWAVE Health on 7 of the 11 factors compared between the two stocks.
SANUWAVE Health Company Profile
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
SI-Bone Company Profile
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for SANUWAVE Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SANUWAVE Health and related companies with MarketBeat.com's FREE daily email newsletter.